# US 2020/0390778 A1 · Compounds and methods for treating oxalate-related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390778 A1
- Document ID: US20200390778A1
- Status: Published application
- Kind: A1
- Application number: 16/971,825
- Filed: 2019-02-22
- Published: 2020-12-17
- Earliest claimed: 2018-02-23
- Assignees: OxaluRx, Inc.
- Applicants: OxaluRx, Inc.
- Inventors: Bradley T. KELLER; John J. TALLEY
- Web page: https://patentgrep.com/patent/US20200390778A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61P 13/12: of the kidneys
- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.

## Claims

### Claim 1

A pharmaceutical composition comprising a compound of structural Formula Ia
or a salt or prodrug thereof, wherein:
W is N or NH;
Y is N if W is NH; Y is NH if W is N;
R1 is chosen from hydrogen and C1-C6 alkyl;
L is O;
R4 and R5 are each independently chosen from hydrogen or C1-C6 alkyl;
A is chosen from monocyclic or bicyclic aryl, monocyclic or bicyclic heteroaryl, biaryl, and biheteroaryl, any of which is optionally substituted with one or more R2 groups; and
each R2 is independently chosen from halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, pentafluorosulfaneyl, sulfamoyl, C1-C6 alkylsulfamoyl, C1-C6 dialkylsulfamoyl, cyano, amino, C1-C6 alkylamino, C1-C6 dialkylamino, hydroxy, and C1-C6 hydroxyalkyl; and
a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein structure of Formula I is a structure of Formula Ib
or a salt or prodrug thereof, wherein all groups are as defined in claim 1; and
a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein structure of Formula I is a structure of Formula Ic
or a salt or prodrug thereof, wherein all groups are as defined in claim 1; and
a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1, 2, 3)

The pharmaceutical composition of any of claims 1 to 3, wherein A is chosen from aryl, biaryl, and biheteroaryl, any of which is optionally substituted with one or more R2 groups.

### Claim 5 (depends on 4)

The compound of claim 4, wherein A is chosen from phenyl, biphenyl, naphthyl, pyridinylphenyl, phenylpyridinyl, and bipyridinyl, any of which is optionally substituted with one or more R2 groups.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein A is substituted with one or more R2 groups chosen from chloro, methyl, methoxy, bromo, dimethyl, fluoro, trifluoromethyl, ethoxy, trifluoromethoxy, difluoromethoxy, methylthio, trifluoromethylthio, cyano, pentafluorosulfaneyl, dichloro, methylsulfinyl, methylsulfonyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl, propyl, butyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolindyl, piperidinyl, azepanyl, morpholinyl, vinyl, methylpropenyl, and ethynyl.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the phenyl is substituted with one or more R2 groups chosen from chloro, methyl, methoxy, bromo, dimethyl, fluoro, trifluoromethyl, ethoxy, trifluoromethoxy, difluoromethoxy, methylthio, trifluoromethylthio, cyano, pentafluorosulfaneyl, dichloro, methylsulfinyl, methylsulfonyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl, propyl, butyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolindyl, piperidinyl, azepanyl, morpholinyl, vinyl, methylpropenyl, and ethynyl.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The pharmaceutical composition of any of claims 1-7, wherein R1 is ethyl, methyl, or hydrogen.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The pharmaceutical composition of any of claims 1-8, wherein R4 and R5 are independently chosen from methyl and hydrogen.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The pharmaceutical composition of any of claims 1-9, wherein R1 is hydrogen.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The pharmaceutical composition of any of claims 1-9, wherein R1 is C1-C6 alkyl.

### Claim 12

A pharmaceutical composition comprising a compound of structural Formula Id
or a salt or prodrug thereof, wherein:
W is N or NH;
Y is N if W is NH; Y is NH if W is N;
R1 is chosen from hydrogen and C1-C6 alkyl;
L is O;
R4 and R5 are each independently chosen from hydrogen or C1-C6 alkyl;
each R2 is independently chosen from halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, pentafluorosulfaneyl, sulfamoyl, C1-C6 alkylsulfamoyl, C1-C6 dialkylsulfamoyl, cyano, amino, C1-C6 alkylamino, C1-C6 dialkylamino, hydroxy, and C1-C6 hydroxyalkyl; and
a pharmaceutically acceptable excipient.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the phenyl is substituted with one or more R2 groups chosen from chloro, methyl, methoxy, bromo, dimethyl, fluoro, trifluoromethyl, ethoxy, trifluoromethoxy, difluoromethoxy, methylthio, trifluoromethylthio, cyano, pentafluorosulfaneyl, dichloro, methylsulfinyl, methylsulfonyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl, propyl, butyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolindyl, piperidinyl, azepanyl, morpholinyl, vinyl, methylpropenyl, and ethynyl.

### Claim 14 (depends on 12, 13)

The pharmaceutical composition of claim 12 or 13, wherein R1 is ethyl, methyl, or hydrogen.

### Claim 15 (depends on 12, 13, 14)

The pharmaceutical composition of any of claims 12-14, wherein R4 and R5 are independently chosen from methyl and hydrogen.

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, wherein the compound is chosen from
or a salt or prodrug thereof.

### Claim 17

A compound of structural Formula Ie
or a salt or prodrug thereof, wherein:
W is N or NH;
Y is N if W is NH; Y is NH if W is N;
R1 is chosen from hydrogen and C1-C6 alkyl;
L is chosen from NH, NR4, O, CR4═CR5, OCR4R5, and SCR4R5;
R4 and R5 are each independently chosen from hydrogen or C1-C6 alkyl;
each R2 is independently chosen from halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, pentafluorosulfaneyl, sulfamoyl, C1-C6 alkylsulfamoyl, C1-C6 dialkylsulfamoyl, cyano, amino, C1-C6 alkylamino, C1-C6 dialkylamino, hydroxy, and C1-C6 hydroxyalkyl;
m and n are independently 1, 2, or 3.

### Claim 18 (depends on 17)

The compound of claim 17, wherein the biphenyl is substituted with one or more R2 groups chosen from chloro, methyl, methoxy, bromo, dimethyl, fluoro, trifluoromethyl, ethoxy, trifluoromethoxy, difluoromethoxy, methylthio, trifluoromethylthio, cyano, pentafluorosulfaneyl, dichloro, methylsulfinyl, methylsulfonyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl, propyl, butyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolindyl, piperidinyl, azepanyl, morpholinyl, vinyl, methylpropenyl, and ethynyl.

### Claim 19 (depends on 17, 18)

The compound of claim 17 or 18, wherein R1 is ethyl, methyl, or hydrogen.

### Claim 20 (depends on 17, 18, 19)

The compound of any of claims 17-19, wherein R4 and R5 are independently chosen from methyl and hydrogen.

### Claim 21 (depends on 17, 18, 19, 20)

The compound of any of claims 17-20, wherein L is O.

### Claim 22 (depends on 21)

The compound of claim 21, chosen from
or a salt or prodrug thereof.

### Claim 23 (depends on 17, 18, 19, 20)

The compound of any of claims 17-20, wherein L is CH═CH.

### Claim 24 (depends on 23)

The compound of claim 23, chosen from
or salt thereof.

### Claim 25 (depends on 17, 18, 19, 20)

The compound of any of claims 17-20, wherein L is OCH2.

### Claim 26 (depends on 25)

The compound of claim 25, chosen from
or a salt or prodrug thereof.

### Claim 27 (depends on 17, 18, 19, 20)

The compound of any of claims 17-20, wherein L is SCH2.

### Claim 28 (depends on 27)

The compound of claim 27, chosen from
or a salt or prodrug thereof.

### Claim 29

A compound chosen from Examples I-001-I-311, or a salt or prodrug thereof.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A pharmaceutical composition as recited in any of claims 1-16, or a compound of any of claims 17-29, or a salt or prodrug thereof, for use as a medicament.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A pharmaceutical composition as recited in any of claims 1-16, or a compound of any of claims 17-29, or a salt or prodrug thereof, for use in the manufacture of a medicament for preventing or treating an oxalate-related disease.

### Claim 32 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A pharmaceutical composition comprising a compound of any of claims 17-29, a salt or prodrug thereof together with a pharmaceutically acceptable carrier.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 32)

The pharmaceutical composition of any of claims 1-16 or claim 32, formulated for oral administration.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 32)

The pharmaceutical composition of any of claims 1-16 or claim 32, additionally comprising another therapeutic agent.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A method of inhibiting glycolate oxidase (GOX) activity in a biological sample comprising contacting the biological sample with a pharmaceutical composition as recited in any of claims 1-16, or a compound of any of claims 17-29, or a salt or prodrug thereof.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A method of treating an oxalate-related disease in a subject in need thereof, comprising the step of administering to the subject a pharmaceutical composition as recited in any of claims 1-16, or a compound of any of claims 17-29, or a salt or prodrug thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the subject is a human.

### Claim 38 (depends on 37)

The method of claim 37, wherein the oxalate-related disease is hyperoxaluria.

### Claim 39 (depends on 36)

The method of claim 36, wherein primary hyperoxaluria is treated.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A method of treating an oxalate-related disease in a subject in need thereof, comprising the sequential or co-administration of a pharmaceutical composition as recited in any of claims 1-16, or a compound of any of claims 17-29; and a second therapeutic agent.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A pharmaceutical composition as recited in any of claims 1-16, or a compound of any of claims 17-29, or a salt or prodrug thereof, for use in human therapy.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A pharmaceutical composition as recited in any of claims 1-16, or a compound of any of claims 17-29, or a salt or prodrug thereof, for use in treating an oxalate-related disease.

### Claim 43 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

Use of a compound of any of claims 17-29, or a salt or prodrug thereof, for the manufacture of a medicament to treat an oxalate-related disease.

### Claim 44

A compound of structural Formula Ia
or a salt or prodrug thereof, wherein:
W is N or NH;
Y is N if W is NH; Y is NH if W is N;
R1 is hydrogen or C1-C6 alkyl;
L is chosen from NH, NR4, S, O, CR4═CR5, OCR4R5, and SCR4R5;
R4 and R5 are each independently chosen from hydrogen or C1-C6 alkyl;
A is chosen from monocyclic or bicyclic aryl, monocyclic or bicyclic heteroaryl, biaryl, and biheteroaryl, any of which is optionally substituted with one or more R2 groups; and
each R2 is independently chosen from halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 heterocycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, pentafluorosulfaneyl, sulfamoyl, C1-C6 alkylsulfamoyl, C1-C6 dialkylsulfamoyl, cyano, amino, C1-C6 alkylamino, C1-C6 dialkylamino, hydroxy, and C1-C6 hydroxyalkyl.
